Skip to main content
letter
. 2017 Aug 25;7(8):e592. doi: 10.1038/bcj.2017.79

Figure 1.

Figure 1

Thirty-day landmark analysis depicting overall survival based on treatment modality in patients with extramedullary myeloid sarcoma (a) age <70 years, and (b) age ⩾70 years.